Procalcitonin as an Early Marker of the Need for Invasive Respiratory or Vasopressor Support in Adults With Community-Acquired Pneumonia

Chest

Volumn 150, Issue 4, 2016, Pages 819-828

  Self, Wesley H ^a   Grijalva, Carlos G ^a   Williams, Derek J ^a   Woodworth, Alison ^a   Balk, Robert A ^b   Fakhran, Sherene ^c   Zhu, Yuwei ^a   Courtney, D Mark ^d   Chappell, James ^a   Anderson, Evan J ^e   Qi, Chao ^d   Waterer, Grant W ^d,f   Trabue, Christopher ^g   Bramley, Anna M ^h   Jain, Seema ^h   Edwards, Kathryn M ^a   Wunderink, Richard G ^d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c Jr Hospital of Cook County   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

biomarkers; pneumonia; prognosis; respiratory failure; septic shock

Indexed keywords

PROCALCITONIN; BIOLOGICAL MARKER; CALCITONIN; VASOCONSTRICTOR AGENT;

ADULT; AGED; ARTIFICIAL VENTILATION; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONFERENCE PAPER; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HIGH RISK POPULATION; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY; BLOOD; COMMUNITY-ACQUIRED INFECTIONS; COMPLICATION; MIDDLE AGED; PNEUMONIA; PROGNOSIS; RESPIRATORY INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; STATISTICAL MODEL; UTILIZATION;

AGED; BIOMARKERS; CALCITONIN; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL CARE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PNEUMONIA; PROGNOSIS; PROSPECTIVE STUDIES; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS;

EID: 84994505167     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.04.010     Document Type: Conference Paper

References (37)

1. 1 Kung, H.C., Hoyert, D.L., Xu, J., Murphy, S.L., Deaths: Final date for 2005. Natl Vital Stat Rep 56:10 (2008), 1–20.
2. 2 Pfuntner A, Wier LM, Stocks C. Most frequent conditions in U.S. hospitals, 2010. HCUP Statistical Brief #148. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb148.pdf. Accessed June 15, 2016.
3. 3 Self, W.H., Grijalva, C.G., Zhu, Y., et al. Rates of emergency department visits due to pneumonia in the United States, July 2006-June 2009. Acad Emerg Med 20:9 (2013), 957–960.
4. 4 Mandell, L.A., Wunderink, R.G., Anzueto, A., et al. Infectious Diseases Society of American/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44:suppl 2 (2007), S27–S42.
5. 5 Ewig, S., Torres, A., Woodhead, M., Assessment of pneumonia severity: A European perspective. Eur Respir J 27:1 (2006), 6–8.
6. 6 Niederman, M.S., Feldman, C., Richards, G.A., Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J 27:1 (2006), 9–11.
7. 7 Fine, M.J., Smith, M.A., Carson, C.A., et al. Prognosis and outcomes of patient with community-acquired pneumonia: a meta-analysis. JAMA 275:2 (1996), 134–141.
8. 8 Dremsizov, T., Clermont, G., Kellum, J.A., et al. Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course?. Chest 129:4 (2006), 968–978.
9. 9 Fine, M.J., Auble, T.E., Yealy, D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:4 (1997), 243–250.
10. 10 Lim, W.S., van der Eerden, M.M., Laing, R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58:5 (2003), 377–382.
11. 11 Charles, P.G.P., Wolfe, R., Whitby, M., et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 47:3 (2008), 375–384.
12. 12 Renaud, B., Labarere, J., Coma, E., et al. Risk stratification of early admission to the intensive care unit of patients with no major criteria of severe community-acquired pneumonia: development of an international prediction rule. Crit Care, 13(2), 2009, R54.
13. 13 Espana, P.P., Capelastegui, A., Gorordo, I., et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 174:11 (2006), 1249–1256.
14. 14 Phua, J., Ngerng, W.J., Lim, T.K., The impact of a delay in intensive care unit admission for community-acquired pneumonia. Eur Respir J 36:4 (2010), 826–833.
15. 15 Dean, N.C., Jones, J.P., Aronsky, D., et al. Hospital admission decision for patients with community-acquired pneumonia: variability among physicians in an emergency department. Ann Emerg Med 59:1 (2012), 35–41.
16. 16 Chen, L.M., Render, M., Sales, A., et al. Intensive care unit admitting patterns in the Veterans Affairs health care system. Arch Intern Med 172:16 (2012), 1220–1226.
17. 17 Dasta, J.F., McLaughlin, T.P., Mody, S.H., Piech, C.T., Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med 33:6 (2005), 1266–1271.
18. 18 Orsini, J., Blaak, C., Yeh, A., et al. Triage of patients consulted for ICU admission during times of ICU-bed shortage. J Clin Med Res 6:6 (2014), 463–468.
19. 19 Chalmers, J.D., ICU admission and severity assessment in community-acquired pneumonia. Crit Care, 13(3), 2009, 156.
20. 20 Renaud, B., Santin, A., Severe community acquired pneumonia: what should we predict?. Crit Care, 13(5), 2009, 421.
21. 21 Assicot, M., Gendrel, D., Carsin, H., et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341:8844 (1993), 515–518.
22. 22 Schuetz, P., Briel, M., Mueller, B., Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections. JAMA 309:7 (2013), 717–718.
23. 23 Ch, Yo, Hsieh, P.S., Lee, Sh, et al. Comparison of the test characteristics of procalcitonin to C-reactive protein and leukocytosis for the detection of serious bacterial infections in children presenting with fever without a source: a systematic review and meta-analysis. Ann Emerg Med 60:5 (2012), 591–600.
24. 24 Musher, D.M., Bebko, S.P., Roig, I.L., Serum procalcitonin level, viral polymerase chain reaction analysis, and lower respiratory tract infection. J Infect Dis 209:4 (2014), 631–633.
25. 25 Kruger, S., Ewig, S., Papassotiriou, J., et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res, 10, 2009, 65.
26. 26 Masia, M., Gutierrez, F., Shum, C., et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patient's outcome research team pneumonia severity index. Chest 128:4 (2005), 2223–2229.
27. 27 Huang, D.T., Weissfeld, L.A., Kellum, J.A., et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 52:1 (2008), 48–58.
28. 28 Schuetz, P., Suter-Widmer, I., Chaudri, A., et al. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J 37:2 (2011), 384–392.
29. 29 Kruger, S., Ewing, S., Marre, R., et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 31:2 (2008), 349–355.
30. 30 Ramirez, P., Ferrer, M., Marti, V., et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med 39:10 (2011), 2211–2217.
31. 31 Jain, S., Self, W.H., Wunderink, R.G., et al. Community-acquired pneumonia requiring hospitalization in US adults. N Engl J Med 373:5 (2015), 415–427.
32. 32 BioMerieux, Inc. VIDAS B.R.A.H.M.S. PCT. BioMerieux, Inc. website. http://www.biomerieux-diagnostics.com/vidas-brahms-pct. Accessed July 15, 2015.
33. 33 American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:4 (2005), 388–416.
34. 34 Ewig, S., Ruiz, M., Mensa, J., et al. Severe community-acquired pneumonia: assessment of severity criteria. Am J Respir Crit Care Med 158:4 (1998), 1102–1108.
35. 35 Harrell, F.E. Jr., Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression and Survival Analysis. 2001, Springer, New York, New York.
36. 36 Kutz, A., Briel, M., Christ-Crain, M., et al. Prognostic value of procalcitonin in respiratory tract infections across clinical settings. Crit Care, 19, 2015, 74.
37. 37 Schuetz, P., Amin, D.N., Greenwald, J.L., Role of procalcitonin in managing adult patients with respiratory tract infections. Chest 141:4 (2012), 1063–1073.